CD39 Screening Services

Cluster of differentiation 39, (CD39), is a cell surface enzyme that is highly expressed on regulatory T cells and plays an important role in modulating immune cell function. CD39 hydrolyzes ATP to ADP which can subsequently be hydrolyzed by CD73 to adenosine..  Adenosine can enhance tumor growth via two mechanisms – 1) binding of adenosine to A2A and A2B receptors expressed on tumor cells directly promotes tumor cell proliferation and 2) binding of adenosine to A2A and A2B receptors on immune cells such as also  inhibits the activity of pro-inflammatory, anti-tumor immune cells like CD4+ T Cells, CTLs, dendritic cells, NK cells, while and activating immunosuppressant cells likeTregs, MDSCs and TAMs.

The properties of the CD39-adenosine pathway outlined above makes it of high clinical significance. Since CD39 is often overexpressed in human cancers inhibition of the CD39-adenosine pathway could serve as a new therapeutic target to enhance immune activation and increase tumor cell death. The development of CD39 antagonistic monoclonal antibodies and small molecule inhibitors have been proposed as potential ways to both treat and prevent cancer. In preclinical studies, inhibitory antibodies have been shown to inhibit the function of regulatory T cells without depleting them.

In addition to the CD39 protein, BPS also offers CD39 screening and profiling services. Trust us to provide you with high quality data with fast turnaround time. Our team of experts along with our broad services portfolio makes it easy to:

• Screen for inhibitors/targets using our CD39 assay
• Select from IC50 determination and single point concentrations
• Receive data within days of compound submission
• Perform follow-up studies using the same soluble receptors manufactured in-house
• Get questions anwered or project guidance in a time-efficient manner